Gujarat Magazine

Hepatic Tumor Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

 Breaking News
  • No posts were found

Hepatic Tumor Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

June 26
19:36 2024
Hepatic Tumor Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Hepatic Tumor Pipeline Insight 2024”report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Hepatic Tumor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Hepatic Tumor Research. Learn more about our innovative pipeline today! @ Hepatic Tumor Pipeline Outlook

Key Takeaways from the Hepatic Tumor Pipeline Report

  • June 2024:- Hoffmann-La Roche- A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver). This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer.
  • June 2024:- AstraZeneca- A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma: ATHENA. A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
  • DelveInsight’s Hepatic Tumor pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Hepatic Tumor treatment.
  • The leading Hepatic Tumor Companies such as Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., Eureka Therapeutics Inc., and others.
  • Promising Hepatic Tumor Therapies such as Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Zimberelimab, Domvanalimab, and others.

Stay informed about the cutting-edge advancements in Hepatic Tumor Treatments. Download for updates and be a part of the revolution in cancer care @ Hepatic Tumor Clinical Trials Assessment

Hepatic Tumor Emerging Drugs Profile

  • Namodenoson: Can Fite Biopharma

Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist. It is an oral drug currently being developed for the treatment of oncology diseases including advanced liver cancer(hepatocellular carcinoma), pancreatic cancer and metabolic associated steatohepatitis (MASH). Currently it is in Phase III stage of clinical trial evaluation to treat Hepatocellular Carcinoma.

  • MTL CEBPA : MiNA Therapeutics

MTL-CEBPA is a novel medicine being developed as a combination therapy in cancer. MTL-CEBPA is designed to reduce immune suppression of myeloid cells by restoring C/EBP-a protein to normal levels using the RNA Activation mechanism. The drug candidate uses the RNA interference mechanism of action. Currently being evaluated in the Phase II studies for the treatment of Hepatic Tumor.

  • Amivantamab: Janssen Research & Development, LLC

Amivantamab is a fully-human EGFR-MET bispecific antibody with immune cell-directing activity that targets tumors with activating and resistance EGFR mutations and MET mutations and amplifications. The drug is based on antibody-dependent cell cytotoxicity mechanism of action. The drug is in Phase II stage of clinical trials for the treatment of Hepatic Tumor.

  • Fostroxacitabine bralpamide: Medivir AB

Fostroxacitabine bralpamide is a small molecule a type of smart chemotherapy that delivers the cell-killing compound selectively to the tumor while minimizing the harmful effect on normal cells. being developed by Medivir AB. It works as Nucleotide DNA polymerase inhibitor. The drug candidate is administered through oral route. Currently the drug is being evaluated in Phase I/II for the treatment of Hepatic Tumor.

  • ETN101: Etnova Therapeutics Corp.

ETN101 is a synthetic drug candidate designed to be a best-in-class anticancer agent targeting hepatocellular carcinoma. It is being developed with the aim of preoccupying the market for both first-line and follow-up treatments of hepatocellular carcinoma with its high rate of complete remission and safety. It inhibits protein activity using FLT3/KIT/VEGFR2/PDGFRB tyrosine kinase inhibitors and its downstream signaling pathways: PI3K/AKT and RAS-MAPK, working as multiple tyrosine kinase inhibitors (mTKI). The drug is in Phase I stage of clinical trials for the treatment of Hepatic Tumor.

Learn more about Hepatic Tumor Drugs opportunities in our groundbreaking Hepatic Tumor Research and development projects @ Hepatic Tumor Unmet Needs

Hepatic Tumor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.

Hepatic Tumor Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Discover the latest advancements in Hepatic Tumor Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Hepatic Tumor Market Drivers and Barriers, and Future Perspectives

Scope of the Hepatic Tumor Pipeline Report

  • Coverage- Global
  • Hepatic Tumor Companies- Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., Eureka Therapeutics Inc., and others.
  • Hepatic Tumor Therapies- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Zimberelimab, Domvanalimab, and others.
  • Hepatic Tumor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Hepatic Tumor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Hepatic Tumor Pipeline on our website @ Hepatic Tumor Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Hepatic Tumor: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Comparative Analysis
  8. Namodenoson: Can Fite Biopharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. MTL CEBPA : MiNA Therapeutics
  12. Early Stage Products (Phase I)
  13. Comparative Analysis
  14. ETN101: Etnova Therapeutics Corp.
  15. Inactive Products
  16. Hepatic Tumor Key Companies
  17. Hepatic Tumor Key Products
  18. Hepatic Tumor – Unmet Needs
  19. Hepatic Tumor – Market Drivers and Barriers
  20. Hepatic Tumor – Future Perspectives and Conclusion
  21. Hepatic Tumor Analyst Views
  22. Hepatic Tumor Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/